Those early results are very positive, and strongly indicate that the nanoparticles could be useful for assessing how effective a therapy is on a much shorter time
scale than current treatments, which usually rely on observing the size of the tumor.
Not exact matches
Limitations of HPP include the
current price (more expensive
than conventional thermal
treatment) and low throughput which restricts
scaling.
As Scientific American reported earlier this year, more
than half of the
current cancer clinical trials do incorporate some form of immunotherapy but still oncologists are often only in the early stages of understanding how to use such
treatment on a larger
scale.